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Abstract
Background: Little is known about longitudinal symptom burden and its consequences for well-
being, and if lifestyle moderates burden in older survivors.
Methods: We report on 36-month data from survivors 60+ with newly diagnosed non-metastatic 
breast cancer and non-cancer controls recruited August 2010-June 2016. Symptom burden was a 
sum of self-reported symptoms/diseases: pain (yes/no), fatigue (FACT-fatigue), cognitive (FACT-
Corresponding author: Jeanne Mandelblatt, MD, MPH, 3300 Whitehaven Blvd, Suite 4100, Washington, DC 20007, USA, 
202-687-0812/fax 202-687-0305, mandelbj@georgetown.edu. 
ClinicalTrials.gov Identifier: NCT03451383
There are no relevant conflicts of interest.
HHS Public Access
Author manuscript
Cancer. Author manuscript; available in PMC 2020 May 28.
Published in final edited form as:
Cancer. 2020 March 15; 126(6): 1183–1192. doi:10.1002/cncr.32663.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
cog), sleep problems (yes/no), depression (CES-D), anxiety (STAI), and cardiac problems and 
neuropathy (yes/no). Well-being was measured using the FACT-G, scaled from 0–100. Lifestyle 
included smoking, alcohol use, BMI, physical activity, and leisure activities. Mixed models 
assessed relationships between treatment group (chemotherapy +/− hormonal, hormonal only, 
control) and symptom burden, lifestyle, and covariates. Separate models tested the effects of 
fluctuations in symptom burden and lifestyle on function.
Results: All groups reported high baseline symptoms, and levels remained high over time; 
survivor-control differences were most notable for cognitive and sleep problems, anxiety, and 
neuropathy. The adjusted burden score was highest among chemotherapy-exposed survivors, 
followed by hormonal therapy vs. controls (p<.001). Burden score was related to physical, 
emotional, and functional well-being (e.g., survivors with lower vs. higher burden scores had 12.4-
point higher physical well-being score). The composite lifestyle score was not related to symptom 
burden or well-being, but physical activity was significantly associated with each outcome (<.005).
Conclusions: Cancer and its treatments are associated with a higher level of actionable 
symptoms and greater loss of well-being over time in older breast cancer survivors than 
comparable non-cancer populations, suggesting the need for surveillance and opportunities for 
intervention.
Precis:
Cancer and its treatments lead to a higher level of actionable symptoms and greater loss of 
function among older breast cancer survivors than expected based on non-cancer control 
experience, suggesting the need for surveillance and intervention.
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Introduction
Many of the nearly four million US breast cancer survivors1 report one or more symptom 
commonly associated with cancer, including cardio-toxic effects, peripheral neuropathy, 
cognitive problems, fatigue, anxiety, depression, and sleep disturbances.2–5 Older women 
(age 60+) constitute the largest segment of breast cancer survivors.1 These older survivors 
may be especially vulnerable to a high symptom burden, and for these symptoms to affect 
functioning, given comorbidities6 and aging.7 We reported that pre-systemic therapy 
symptoms predicted 24-month function.8 However, there are little data on changes in 
symptom burden over time in older survivors. Additionally, recommended healthy lifestyles,
9
 have not been examined for their ability to moderate symptoms or improve function in 
older survivors.
We used data from the Thinking and Living with Cancer (TLC) cohort10 of older breast 
cancer survivors followed from pre-systemic treatment for 36-months. We included data 
from a frequency-matched non-cancer control group to test if symptom burden in older 
survivors exceeded those seen over 36-months the non-cancer population. Finally, we also 
examined whether higher symptom burden decreased physical, emotional and functional 
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well-being, and explored whether healthy lifestyles moderated symptoms or improved well-
being. These data are intended to inform discussions about survivorship care for older 
survivors.
Methods
This study was conducted at Georgetown University and affiliated practices (Washington, 
DC area), Memorial Sloan Kettering Cancer Center (New York), Moffitt Cancer Center 
(Tampa), City of Hope Cancer Center (Los Angeles), Hackensack University Medical 
Center (New Jersey), Indiana University (IU) (Indianapolis), and University of California 
(Los Angeles, UCLA). UCLA provides laboratory support and IU did not begin accrual until 
mid-2016, so data in this report are from the five other sites. All Institutional Review Boards 
approved the protocol.
Setting and Population
We included participants recruited between August 1, 2010 and June 1, 2016 since they had 
the opportunity to complete 36-month assessments; follow-up is ongoing. Eligible survivors 
were aged 60+, had newly diagnosed non-metastatic breast cancer, and were English-
speaking. Those with stroke, head injury, major Axis I psychiatric or neurodegenerative 
disorders, and other recent cancer (<5 years) or past systemic therapy were ineligible. 
Among eligible survivors, 375 (37.2%) consented (consent rate range across sites 17.2–
80.4%, median 63.5%). Consenting survivors were similar in age to non-participants. There 
were 375 consenting age-, race-, education- and site-frequency-matched non-cancer 
controls. Controls met the same exclusion criteria as survivors.
Participants were screened using the Mini-Mental State Examination (MMSE) and the Wide 
Range Achievement Test, 4th edition Word Reading subtest; those with scores of <24 or <3rd 
grade-equivalent reading level, respectively, were ineligible (1 control, 1 survivor). Data for 
survivors who experienced a recurrence (n=8) were excluded for the six months before 
recurrence; one survivor recurred close to baseline and was excluded. Eleven consenting 
survivors and nine controls did not complete baseline. The final sample included 362 
survivors and 365 controls (Figure 1). Among participants remaining alive and eligible, 
74.5% 73%, 65% of survivors and 87.8%, 79.9%, 70.2% of controls completed 12-, 24-, and 
36-month assessments, respectively.
Data Collection
Data collection included survey (all) and medical record data (survivors) and has been 
described previously.10
Measures
Outcomes were symptom burden and physical, emotional, and functional well-being. 
Symptom burden was defined as the sum of self-reported illnesses and symptoms: cardiac 
disease and peripheral neuropathy, depression, anxiety, fatigue, cognitive problems, pain, 
and sleep problems. Symptoms were counted as yes/no or present if continuous score was 
>1.0 SD of the baseline control; this cut-point was based on common conventions.11 Sixteen 
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controls with scores >3SD from the control means were excluded as outliers based on study-
specific protocols.
We selected these eight symptoms/illnesses since they tend to cluster8 and/or include known 
treatment effects (e.g., neuropathy).2 We included myocardial infarction, congestive heart 
failure, arrhythmia, and angina as possible treatment-toxicity related. Scores ≥16 on the 
Center for Epidemiologic Studies Depression (CES-D) Scale defined clinical depression 
(alpha=.86).12 The State-Trait Anxiety Inventory (STAI) measured state anxiety (Cronbach’s 
alpha=.86).13 Fatigue was assessed using the FACT-fatigue scale (alpha=.90).14 Cognitive 
problems were assessed using the FACT-cog (alpha=.90).15
Well-being was measured with FACT-G scales for physical (alpha= .77), and emotional 
(alpha= .77) and functional well-being (alpha= .82)16 We used the FACT-G rather than 
FACT-B to examine survivors in relation to a non-cancer control group. Scores were 
rescaled from 0–100, with higher scores representing better well-being. Minimum clinically 
important differences on the 0–100 scale were 8.3–12.5.17
Covariates
The main predictor of symptom burden was treatment group (chemotherapy +/−hormonal 
treatment, hormonal only, non-cancer control). Lifestyle was based on American Cancer 
Society recommendations scored from 0 to 5, where 5 is the healthiest:9 physical activity 
(600+ mets/week), alcohol (0–1 vs. >1 serving per day), BMI (<30 vs. 30+), past or never 
smoking s vs. currently smoking, and having more vs. less leisure activities.
Potential covariates included race (white vs. non-white), education (years), and marital 
status, comorbid illnesses not considered cancer-related (e.g., hypertension, diabetes), and 
surgery and breast radiotherapy (for cases). Site was included to capture unmeasured setting-
specific variability.
Statistical Analysis
ANOVA, chi-squared tests, and Exact tests were used to compare characteristics by 
treatment-group and evaluate potential confounders.
Random-effects fluctuation mixed models tested the effect of treatment-group and lifestyle 
on symptom burden using data from up to four observation points (baseline, 12, 24, and 36-
months). Lifestyle was included as a between-person (having an average lifestyle that 
differed from the average of other participants) and a within-person predictor (having 
healthier lifestyle compared to one’s own average).18 Covariates included age, race, site, and 
other comorbidities not included as symptoms.
Separate random-effects fluctuation models examined how treatment-group and symptom 
burden were related to physical, emotional, and functional well-being. Surgery type and 
radiation were not related to outcomes, so were not included in the treatment groups. 
Covariates included lifestyle, age, race, site, and other comorbidities. Since some of the 
well-being scales included 1–2 items about symptoms, we repeated analyses excluding those 
items from the well-being scale, and the relationship of symptoms and well-being were 
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unchanged; we present data with the full well-being scales for comparability to other 
studies.
Since drop-out or death can lead to informative missing data respect to outcomes, we used 
baseline covariates for inverse probability weighting to reduce bias and boost efficiency.19 
Results without weighting were similar to weighted results.
Finally, to explore how each symptom affected the relationship between treatment and well-
being, we built a series of step-wise models progressively adding each individual symptom 
one at a time and examining the change in the model goodness-of-fit (Akaike Information 
Criterion [AIC]); we repeated this process to evaluate the individual components of the 
composite lifestyle measure.
In all models, estimates reaching two-sided p<0.05 were considered statistically significant. 
When multiple (K) comparisons were performed for a set of analyses, we used the 
conservative Bonferroni adjusted type I error (0.05/K). Analyses were conducted using SAS 
Version 9.4.b (SAS Institute Inc., Cary, NC, USA).
Results
Participants were 60 to 98 years old (Table 1). There was a high rate of all symptoms at 
baseline before systemic therapy. Over time, survivors treated with chemotherapy (+/
−hormonal treatment) tended to have the highest levels of peripheral neuropathy, depression, 
and pain. Survivors exposed to either chemotherapy (+/−hormonal treatment) or hormonal 
therapy exhibited a pattern of elevated fatigue, sleep disturbance, and cardiovascular 
problems compared to controls over time. (Figure 2).
Symptom Burden
The adjusted symptom burden was greatest for survivors who received chemotherapy +/
−hormonal therapy, followed by survivors who received hormonal therapy, then controls, 
considering covariates (p<.001, Table 2). Lifestyle was not related to symptoms and did not 
change the treatment-group effect, (Table 2) but higher physical activity reduced symptoms 
(p=.04). Interactions between lifestyle and treatment were not significant, so were not 
included in the final symptom model.
Well-being
Treatment-group was associated with physical, functional and emotional well-being scales. 
When a woman’s symptom burden was higher than other women or than the woman’s usual 
level, her well-being score was worse (p. 001)(Table 3). The magnitude of effect of 
symptoms on each well-being scale was clinically meaningful. For instance, when a woman 
had a greater vs. lower symptom burden, her adjusted physical well-being score was 12.4 
points lower (p <.001). Survivors had higher symptom burden than controls, but the impact 
of symptom burden on well-being did not differ by group. Lifestyle was not related to well-
being and did not change the impact of treatment or symptoms on well-being, (Table 3) but 
greater physical activity was associated with better physical and functional well-being 
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(p<.004). Interaction terms There was no significant interaction between symptoms and 
lifestyle in effect on well-being and were not retained in the final models.
Effects of Specific Symptoms on Well-being
Each individual symptom was significantly related to physical well-being, with the largest 
effects seen for depression, pain, and sleep disturbance (Table 4). Similar results were seen 
for emotional and functional well-being (not shown).
DISCUSSION
This study illustrates that over the 36-months after diagnosis older breast cancer survivors 
have a higher symptom burden than seen in similar older women without cancer. The highest 
magnitude of effect of treatment on symptom burden was seen for those exposed to 
chemotherapy (+/− hormonal therapy), but those on hormonal therapy alone also had a 
significantly greater symptom burden than women without cancer. Higher symptom burden 
was significantly associated with clinically meaningful declines in well-being. Composite 
lifestyle did not moderate treatment effects, independently ameliorate symptoms, or improve 
function, but the individual component of physical activity did improve outcomes.
The rates of symptoms in this study are similar to other reports,20–22 except for less 
peripheral neuropathy.23 By including a non-cancer group, we were able to demonstrate that 
older breast cancer survivors experienced a higher burden of symptoms and decrement in 
function than controls. These findings could inform long-term clinical care to address the 
persistent effects of treatment, since symptoms could affect completion of hormonal therapy.
It has been more than a decade since the Institute of Medicine highlighted the unmet needs 
of cancer survivors,24 but 50% of survivors still report not getting help to address symptoms.
25
 These data, together with our findings, suggest that survivorship care should emphasize 
screening for and discussion of symptoms including sleep difficulties, depression, anxiety, 
pain, and fatigue,26 especially since these symptoms are actionable. System-level 
interventions like chart reminders might increase symptom screening, since oncologists with 
training about cancer-related symptoms or who use electronic records with prompts are more 
likely to talk to survivors about care needs.27 Professional guidelines could also place 
greater emphasis on symptom recognition and management. Addressing symptom burden is 
especially salient for older survivors, since our results demonstrate that symptom burden was 
associated with clinically meaningful decrements in well-being.
We did not find benefits for healthy lifestyles, perhaps since we had limited sensitivity and 
variability in this measure. We did find that being more physically active did reduce 
symptoms and improve well-being. Lifestyle interventions including exercise,28,29 
reductions in sedentary time,30 yoga,31 cognitive re-training,32 and weight loss have been 
shown to increase well-being in other studies,33–36 so this remains an important topic for 
survivorship care visits.37
Our study has many strengths, including a large sample, a non-cancer control group, and 
data over 36-months. There are also several caveats that should be noted in considering our 
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results. First, it is difficult to attribute symptoms to cancer, but having a control group 
allowed valid inference regarding differences in matched cancer vs. non-cancer populations. 
Use of an additively-scored symptom checklist approach like ours has been used in similar 
studies with good concurrent validity.38,39 Second, we did not measure all possible 
symptoms, such as lymphedema, post-tramautic stress disorder, sexual dysfunction, or 
financial stress; these are important to consider in future research. Third, it is difficult to 
show indivudal changes in symptoms over time, but our fluctuation models tested the effects 
of having a different symptom burden at each time point. Fourth, we did not include social 
well-being ,since we this varied based on need, rather than QOL. Fifth, we had limited 
variabilty in lifestyle; this remains an important area for more research. Finally, our cohort 
was well-educated, and may not represent all older survivors. However, given the strong 
association of socioeconomic status and health,40 our rates of symptoms and impact on 
function may underestimate those in broader populations.
Overall, this study moves the field forward by demonstrating that cancer and its treatments 
lead to a higher level of actionable symptom burden, and greater loss of well-being over the 
first 36-months than expected based on the experience of matched non-cancer controls. 
Future research is needed to understand factors that contribute to resilience or vulnerability 
to a high symptom burden and functional decline. Until then, survivorship care 
guidelines9,41 should include clear recommendations for surveillance and treatment of 
symptoms among older survivors.
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Figure 1. 
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The top panel represents survivors and the bottom panel represents non-cancer controls. The 
percent consenting and refusing was calculated among those alive and eligible at each time 
point; participants become ineligible if they develop another cancer, or any cancer if a 
control, neurological disease, or, for survivors, have a recurrence. Numbers at 36-months 
drop due to administrative loss from a gap in funding. Participants may have refused one 
interview, but completed later interviews. Sixty-nine percent of participants completed three 
or four assessments, 15.2% completed two, and 16.3% completed baseline only. There were 
no significant differences in age, race, or education by number of completed assessments.
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Figure 2. 
Percent of Older Breast Cancer Survivors and Non-Cancer Controls Reporting Specific 
Symptoms by Treatment and Time
Difference significant for cognitive problems (p=.01), anxiety (p=.01), sleep (p=.02), and 
neuropathy (p=.014) (note Bonferroni corrected p value =.05/8, or p=.00625).
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Table 1.
Baseline Characteristics of Older Breast Cancer Survivors and Non-Cancer Controls
Non-Cancer Controls1 
N=349
Survivors N=3621
Chemo +/−Hormonal N=99 Hormonal Only N=249 p-value
%(n) or mean(SD)
Socio-demographic
Age, Mean SD (range) 68.0(7.0) (60 – 91) 66.2(4.8) (60 – 84) 68.6(6.3) (60 – 98) 0.007
Race 0.908
 White 78.4(273) 78.8(78) 79.9(199)
 Non-White 21.6(75) 21.2(21) 20.1(50)
Married vs. not 48.5(166) 59.2(58) 61.3(144) 0.006
Education, years 15.4(2.3) 15.3(2.2) 15.1(2.1) 0.270
Clinical (cases only)
Stage <.001
 DCIS - 0.0(0) 15.7(39)
 Stage 1 - 40.4(40) 61.0(152)
 Stage 2 - 44.4(44) 22.1(55)
 Stage 3 - 15.2(15) 1.2(3)
ER Status <.001
 Positive - 69.7(69) 99.6(248)
 Negative - 30.3(30) 0.4(1)
Surgery 0.110
 Breast conserving surgery - 50.5(50) 59.9(148)
 Mastectomy - 49.5(49) 40.1(99)
Radiotherapy (BCS only) - 45.5(45) 59.0(147) 0.022
Lifestyle Factors
Smoking Status 0.073
 Current 3.6(12) 9.4(9) 5.6(13)
 Former/never 96.4(321) 90.6(87) 94.4(219)
Alcohol Use 0.252
 </= 1 drink/day 78.4(240) 85.5(71) 76.9(163)
 > 1 21.6(66) 14.5(12) 23.1(49)
IPAQ physical Activities (MET/week)2 <.001
 <600 20.5(66) 36.6(30) 35.5(70)
 >/= 600 79.5(256) 63.4(52) 64.5(127)
BMI 0.026
 >=30 24.6(82) 36.1(35) 33.1(79)
 <30 75.4(251) 63.9(62) 66.9(160)
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Non-Cancer Controls1 
N=349
Survivors N=3621
Chemo +/−Hormonal N=99 Hormonal Only N=249 p-value
%(n) or mean(SD)
Leisure Activities3 6.6(2.0) 6.9(2.1) 6.4(2.1) 0.129
Baseline Well-being4
Physical, mean(SD) 92.1(9.0) 82.7(15.8) 82.8(16.1) <.001
Emotional, mean(SD) 91.4(9.4) 74.2(20.1) 84.3(15.3) <.001
Functional, mean(SD) 84.6(14.6) 71.9(21.3) 73.4(20.4) <.001
Baseline Symptoms
Pain 53.8(182) 68.5(63) 61.6(138) 0.021
Fatigue5 15.4(52) 32.3(30) 36.2(81) <.001
Self-reported cognition 130.5(14.0) 129.0(17.4) 128.4(18.7) 0.317
Anxiety7 15.3(51) 37.6(35) 28.7(64) <.001
Sleep problems 24.6(83) 35.5(33) 37.6(85) 0.003
Depression8 3.6(12) 23.3(21) 10.5(23) <.001
Cardiac disease 7.7(26) 5.4(5) 10.7(24) 0.245
Peripheral neuropathy 0.0(0) 1.0(1) 0.0(0) 0.049
ER=estrogen receptor
1.Numbers may not add to 100% due to missing data; 14 survivors missing therapy. Non-white includes Black, Hispanic, and AAPI; one control 
missing race. P- values for differences between the three groups based on chi-square, Anova, or Fisher’s exact.
2.
Mets are calculated from the IPAQ.
3.
There were 11 leisure activities reported as yes/no.
4.
The well-being based on the FACT-G.16 Scores were normalized from 0–100. Higher scores=greater well-being.
5.
Fatigue scores based on the FACT-fatigue.14 Higher scores=less fatigue.
6.Self-reported cognition was based on the FACT-Cog.15 Higher scores= indicating cognition.
7.
Based on the STAI State Anxiety Scale.13 Higher scores=more anxiety.
8.
Depression defined by score above 16 on the CES-D.12
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Table 2.
Factors Associated with Symptoms Burden among Older Breast Cancer Survivors and Non-cancer Controls
Treatment Model n=653 Treatment and Lifestyle Model N=653
Beta (SE) p-value Beta (SE) p-value
Treatment <.001 <.001
Chemotherapy vs. control 0.77(0.15) 0.78(0.15)
Hormonal vs. control 0.48(0.11) 0.50(0.11)
Lifestyle
 Between-person lifestyle 0.00(0.06) 0.982
 Within-person lifestyle 0.16(0.04) <.001
AIC 5728.0 5653.3
Random-effects mixed fluctuation models; controlling for other comorbidities at baseline, age, race, site. Considers inverse probability of dropping 
out or dying.
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Table 3.
Associations of Symptom Burden and Well-Being Outcomes over 36-Months among Older Breast Cancer 
Survivors and Non-cancer Controls
Physical Well-being1 N=653 Emotional Well-being1 N=653 Functional Well-being1 N=653
Beta (SE) P-value2 Beta (SE) P-value2 Beta (SE) P-value2
Other Comorbidities −0.65(0.18) 0.0004 −0.38(0.26) 0.1353 −0.26(0.28) 0.3382
Treatment Group
 Chemo vs. control −2.34(0.92) 0.0018 −5.87(1.28) <0.0001 −2.18(1.38) 0.2753
 HT vs. control −2.06(0.65) −0.98(0.91) −0.75(0.98)
Symptom Burden
Between-person effect −4.95(0.25) <0.0001 −4.88(0.35) <0.0001 −8.04(0.38) <0.0001
Within-person effect −4.15(0.25) <0.0001 −3.63(0.29) <0.0001 −5.73(0.35) <0.0001
Lifestyle
Between-person lifestyle 0.72(0.36) 0.0449 −0.27(0.50) 0.5874 0.76(0.54) 0.1603
Within-person lifestyle 0.71(0.39) 0.0671 −0.93(0.46) 0.0446 1.07(0.55) 0.0521
AIC 11833.5 12480.1 12979.5
1.
Random-effects mixed fluctuation models, controlling for age, race, site, considering probability of dropping out or dying, predicting FACT-G 
scale scores.16
2.
The Bonferroni corrected significance level is p= .05/3, or p=.0167.
Cancer. Author manuscript; available in PMC 2020 May 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mandelblatt et al. Page 17
Table 4.
Impact of Individual Symptoms on Physical Well-Being among Older Breast Cancer Survivors and Non-
cancer Controls
Base Model 1 
N=653
Cognitive 
Problems 
Model 1 
N=648
Pain Model 1 
N=648
Sleep 
Problems 
Model 1 
N=648
Fatigue 
Model 1 
N=648
Depression 
and Anxiety 
Model 1 
N=645
Neuropathy 
and Cardiac 
Disease 
Model 1 
N=645
Beta (SE)
Comorbidity
−1.78(0.23)** −1.62(0.21)** −0.73(0.20)** −0.71(0.19)** −0.17(0.17) −0.18(0.16) −0.20(0.16)
Treatment
Chemo v. 
control
−6.55(1.17)** −5.74(1.09)** −4.13(0.96)** −3.55(0.94)** −2.40(0.80)** −2.04(0.77)** −1.82(0.81)**
HT v. control
−4.74(0.83)** −4.32(0.78)** −3.62(0.68)** −3.05(0.67)** −1.72(0.58)** −1.79(0.55)** −1.90(0.55)**
Cognition
Within person
−2.78(1.07)** −1.91(1.00) −1.82(0.98) −0.72(0.92) 0.25 0.91) 0.66(0.92)
Between 
person
−6.67(1.51)** −6.33(1.38)** −5.49(1.36)** −2.10(1.25) −2.43(1.25) −2.77(1.26)*
Pain
Within person
−7.76(0.69)** −7.70(0.68)** −6.57(0.64)** −6.92(0.63)** −6.83(0.63)**
Between 
person
−4.06(1.12)** −3.17(1.10)** −2.15(0.99)* −2.11(0.96)* −2.10(0.96)*
Sleep
Within person
−4.05(0.75)** −2.63(0.71)** −1.67(0.70)* −1.62(0.70)*
Between 
person
−1.65(1.18) −0.73(1.06) −0.82(1.05) −0.95(1.06)
Fatigue
Within person
−9.68(0.80)** −8.71(0.79)** −8.67(0.79)**
Between 
person
−4.38(1.24)** −4.34(1.22)** −4.42(1.22)**
Anxiety
Within person −0.71(0.81) −0.64(0.81)
Between 
person
3.55(1.22)** 3.63(1.22)**
Depression
Within person
−10.6(1.29)** −10.9(1.29)**
Between 
person
1.20(1.92) 1.38(1.93)
Peripheral neuropathy
Within person −1.07(2.18)
Between 
person
−0.42(3.65)
Cardiovascular
Within person −0.55(1.33)
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Base Model 1 
N=653
Cognitive 
Problems 
Model 1 
N=648
Pain Model 1 
N=648
Sleep 
Problems 
Model 1 
N=648
Fatigue 
Model 1 
N=648
Depression 
and Anxiety 
Model 1 
N=645
Neuropathy 
and Cardiac 
Disease 
Model 1 
N=645
Between 
person
1.94(1.73)
AIC 12381.1 12153.4 11850.6 11779.0 11431.7 11208.4 11152.4
Random-effects fluctuation models; base model includes other baseline comorbidity, age, race, site, treatment group, and considers inverse 
probability of dropping out or dying.
*p values <0.05
**p-value of <0.001
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